References
- Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau A, et al. Eaaci/ga(2)len/edf/wao guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64:1417–1426.
- O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136:197–201.
- Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C, et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy. 2003;58:621–623.
- Zuberbier T, Ifflander J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol. 1996;76:295–297.
- Tokura Y, Kobayashi M, Kabashima K. Epidermal chemokines and modulation by antihistamines, antibiotics and antifungals. Exp Dermatol. 2008;17:81–90.
- Kobayashi M, Kabashima K, Nakamura M, Tokura Y. Downmodulatory effects of the antihistaminic drug bepotastine on cytokine/chemokine production and cd54 expression in human keratinocytes. Skin Pharmacol Physiol. 2009;22:45–48.
- Moniaga CS, Egawa G, Doi H, Miyachi Y, Kabashima K. Histamine modulates the responsiveness of keratinocytes to IL-17 and TNF-alpha through the H1-receptor. J Dermatol Sci. 2010.
- Sugita K, Kobayashi M, Mori T, Kabashima K, Nakamura M, Tokura Y. Antihistaminic drug olopatadine down modulates ccl17/tarc production by keratinocytes and Langerhans cells. J Dermatol. 2009;36:654–657.
- Kobayashi M, Yoshiki R, Sakabe J, Kabashima K, Nakamura M, Tokura Y. Expression of toll-like receptor 2, nod2 and dectin-1 and stimulatory effects of their ligands and histamine in normal human keratinocytes. Br J Dermatol. 2009;160:297–304.
- Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol. 1998;138:635–638.
- Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676–682.
- Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999;104:1071–1078.
- Otsuka A, Honda T, Doi H, Miyachi Y, Kabashima K. An H1-histamine receptor antagonist decreases serum interleukin-31 levels in patients with atopic dermatitis. Br J Dermatol. 2011;164:455–456.
- Hide M, Furue M, Ikezawa Z, Shiohara T, Furukawa F, Matsunaga K, et al. Guidelines for the diagnosis and treatment of urticaria and angioedema. J Dermatol. 2005;115:703–715.
- Clough GF, Bennett AR, Church MK. Effects of H1 antagonists on the cutaneous vascular response to histamine and bradykinin: a study using scanning laser Doppler imaging. Br J Dermatol. 1998;138:806–814.